This work reveals the complexity of protectively immunity – with the suggestion that multiple types of immune responses together, comprise an immune correlate thus implicating polyfunctional immune control of HIV-1 transmission

This work reveals the complexity of protectively immunity – with the suggestion that multiple types of immune responses together, comprise an immune correlate thus implicating polyfunctional immune control of HIV-1 transmission. one, the RV144 pox virus prime, protein boost (ALVAC/AIDSVAX SLx-2119 (KD025) B/E) vaccine, showed a low level of vaccine protection with an estimated 31% vaccine efficacy (8). Candidate vaccines have sought to elicit both antibody and T-cell responses, but to fully prevent the acquisition of infection, a major focus has been on the induction of protective antibody responses (9,10). Hence, the focus of this issue ofImmunologic Reviewsis Antibodies and Immunity to HIV. Animal models have demonstrated that passive administration of HIV-1– neutralizing antibodies can fully protect against infection, but the induction of such antibodies via immunization remains a major scientific challenge. With recent advances in the isolation and characterization of broadly neutralizing antibodies (bnAbs) from HIV-1-infected subjects, in elucidating structures of the HIV-1 envelope glycoprotein (Env), in defining novel approaches to immunogen design, SLx-2119 (KD025) and in improved understanding of the immunological pathways leading to bNAb elicitation, the challenge developing an HIV-1 vaccine appears to be more tractable. The articles in this issue highlight both major areas of HIV-1 vaccine development progress and remaining obstacles, and provide context for the renewed optimism that a highly effective vaccine, while not imminent, is possible. == Main Text == The HIV-1 vaccine field has now realized that development of a safe and globally effective HIV-1 vaccine will require a greater level of understanding of host-virus interactions than has ever been required or achieved for any previous vaccine, (1012). This is necessitated TUBB3 by a unique combination of virological and immunological characteristics that make protection against HIV-1 infection particularly difficult. Upon infection, HIV-1 genes are incorporated into the host genome, leading to a latent pool of infected CD4+ T cells that are resistant to removal by either anti-retroviral treatment (ART) or by the host immune system. Chronic ongoing replication outpaces the ability of the immune system to control HIV-1 infection and outfits the virus with unfavorable characteristics, including extraordinary antigenic diversity, heavy glycosylation and the shielding of potentially vulnerable Env epitopes. The induction of effective antibodies to HIV-1 Env is further complicated by the high level of somatic hypermutation (SHM) associated with potent neutralization, and the limitation of bnAb B cell lineage development by host immune tolerance mechanisms. The only HIV-1 vaccine efficacy trial that showed some protection (estimated 31% vaccine efficacy at 42 months) was carried out by the US Army and the government of Thailand using a canarypox vector (ALVAC) and a bivalent gp120 boost (AIDSVAX B/E) (8). The trial, called RV144, was conducted in Thailand where the predominant HIV-1 strain was CRF01_AE. Studies of the immune correlates of decreased transmission risk in RV144 demonstrated that antibodies to the second variable (V2) loop were associated with lower risk of infection. These antibodies were not able to neutralize (tier 2) HIV-1 primary isolate strains, but were able to mediate antibody dependent cellular cytotoxicity (ADCC). To follow up on the RV144 trial, a new trial using a similar design but with clade C envelope inserts (ALVAC-C prime, ALVAC + C/C gp120 boost) is now planned for South Africa where the epidemic is most pressing (13). SLx-2119 (KD025) In parallel with these plans, vaccine researchers continue to focus on the difficult task of developing a vaccine that is able to induce broadly neutralizing antibodies (bnAbs), i.e. antibodies that can potently neutralize the majority of diverse circulating strains of HIV-1 (9,10). Such bnAbs can be made, but thus far, only in the setting of HIV infection, and only years after HIV transmission. Thus, the HIV-1 vaccine field is pursuing a two-pronged approach for vaccine developmentfirst to design immunogens and adjuvants that will result in increased vaccine efficacy from that seen in RV144, and second to design immunogens and immunization strategies that will result in induction of the difficult-to-induce antibodies that can neutralize tier 2 HIV-1 primary isolates. Critical questions addressed in this volume of Immunological Reviews are: 1) Why do bnAbs develop in HIV-infected individuals but not in the setting of vaccination? 2) How are bnAbs regulated compared to easily-induced non-neutralizing or tier 1-virus neutralizing antibodies? 3) Are there characteristics of HIV-infected individuals who make bnAbs that can help define strategies to induce bnAbs? 4) What are preferred structures or forms of immunogens that are needed to induce bnAbs? 5) Are there additional strategies for use of antibodies to prevent HIV transmission other than via vaccine induction.